Skip to Content

'
Joe Y. Chang, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Section Chief, Thoracic Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Stereotactic Radiotherapy Program, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston

Education & Training

Degree-Granting Education

1997 The University of Texas MD Anderson Cancer Center, Houston, TX, PHD, Cancer Biology
1988 Graduate School, Fudan University, Shanghai, China, MS, Immunology
1985 Shanghai Medical College, Fudan University, Shanghai, China, MD, Medicine

Postgraduate Training

7/1997-7/2002 Clinical Residency, Radiation Oncology, Rush-Presbyterian St. Luke Medical Center, Chicago, IL
7/1990-7/1993 Visiting Scientist, Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1988-7/1990 Research Residency, Clinical and Translational Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Board Certifications

1/2002 American Board of Radiology (Radiation Oncology)

Experience/Service

Academic Appointments

Associate Professor (tenure), Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-8/2013

Honors and Awards

2008 Travel Award, American Radium Society
2007-2012 America's Top Oncologists, Consumers' Research Council of America
2005-2006 America's Top Radiologist, Consumers' Research Council of America
2004-2005 America's Top Physicians Award, Consumers' Research Council of America
2004 Career Developmental Award, University of Texas Lung Cancer Spore, NIH
2004 RSNA Research Scholar Award, RSNA
2000 ASTRO 2000 Annual Meeting Travel Award, ASTRO
2000 First Place Winner of Resident Research Competition, Rush-Presbyterian St. Luke's Medical Center
1995-1997 NIH Research Training Award, NIH
1995 Dr. Alexander Y. Wang Memorial Award, Society of Chinese Bioscientist in America
1995 First Place Winner of John P. McGovern Graduate Student Award, Graduate School of Biomedical Sciences, The University of Texas M. D. Anderson Cancer Center
1985 Shanghai Outstanding Medical Graduates (Top 10) Award, Shanghai Municipal Government

Professional Memberships

American College of Radiology (ACR) Appropriateness Criteria Radiation Oncology Lung Cancer Committee
Chair for Expert panel in lung cancer, 7/2011-present
International Association for the Study of Lung Cancer
Member-Advanced Radiation Technology Committee, 2013-present
Particle Therapy Co-Operative Group (PTCOG)
Chair of Thoracic Sub-committee, 5/2013-present
Quality Research in Radiation Oncology (ORRO), Philadelphia, PA
Member, 2005-present
Radiation Therapy Oncology Group (RTOG), Philadelphia, PA
Member, Lung and Translational Research Committee, 2005-present
Radiological Society of North American
Research Scholar, 2004-2006
Sino-American Network for Therapeutic Radiology and Oncology (SANTRO)
President, 10/2011-2014
Founding board of directors, 2006-present
The American Society for Therapeutic Radiology and Oncology
Member, 1997-present
The American Society of Clinical Oncology
Member, 2002-present

Selected Publications

Peer-Reviewed Original Research Articles

1. He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimalrRadiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 9(9):1398-1405, 9/2014. PMID: 25122435.
2. Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiother Oncol. e-Pub 8/2014. PMID: 25108807.
3. Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther. e-Pub 7/2014. PMID: 25054431.
4. Zhuang H, Yuan Z, Chang JY, Wang J, Pang Q, Zhao L, Wang P. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol 9(6):882-885, 6/2014. PMID: 24828665.
5. Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, Wu X, Gu J. Telomere Length in Peripheral Blood Leukocytes and Lung Cancer Risk: A Large Case-Control Study in Caucasians. Cancer Res 74(9):2476-2486, 5/2014. e-Pub 3/2014. PMID: 24618342.
6. Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. J Thorac Dis 6(4):348-355, 4/2014. PMCID: PMC3968555.
7. Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG, Roth JA. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys 88(5):1120-1128, 4/2014. PMID: 24661665.
8. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus 27(2):168-175, Feb-Mar, 2/2014. e-Pub 4/2013. PMCID: PMC3740061.
9. Li Y, Kardar L, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys 41(2):021721, 2/2014. PMID: 24506612.
10. Grant JD, Chang JY. Proton-Based Stereotactic Ablative Radiotherapy in Early-Stage Non-Small-Cell Lung Cancer. Biomed Res Int 2014:389048, 2014. e-Pub 7/2014. PMCID: PMC4124720.
11. Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities. Lung Cancer 82(2):252-259, 11/2013. e-Pub 8/2013. PMCID: PMC3839043.
12. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, Mohan R, Rozner MA, Dougherty AH. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat Oncol Biol Phys 87(3):570-575, 11/2013. PMID: 24074931.
13. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac (18)F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 109(1):82-88, 10/2013. e-Pub 9/2013. PMID: 24016676.
14. McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol 109(1):38-44, 10/2013. e-Pub 9/2013. PMID: 24016675.
15. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-147, 9/2013. PMID: 23920393.
16. Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG. Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer. Cancer 119(18):3402-3410, 9/2013. e-Pub 6/2013. PMCID: PMC3775964.
17. Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? Thorac Surg Clin 23(3):369-381, 8/2013. PMID: 23931020.
18. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P. Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non-Small Cell Lung Cancer in Never Smokers. Cancer Res 73(13):4028-4038, 7/2013. e-Pub 5/2013. PMCID: PMC3719971.
19. Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86(4):665-670, 7/2013. e-Pub 5/2013. PMID: 23688815.
20. Pan T, Riegel AC, Ahmad MU, Sun X, Chang JY, Luo D. New weighted maximum-intensity-projection images from cine CT for delineation of the lung tumor plus motion. Med Phys 40(6):061901, 6/2013. PMID: 23718592.
21. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-1319, 5/2013. e-Pub 1/2013. PMCID: PMC3629895.
22. Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE, Expert Panel on Radiation Oncology-Lung. ACR Appropriateness Criteria® Radiation Therapy for Small-Cell Lung Cancer. Am J Clin Oncol 36(2):206-213, 4/2013. PMID: 23511336.
23. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 31(7):895-902, 3/2013. e-Pub 1/2013. PMCID: PMC3577951.
24. Rosenzweig KE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Langer CJ, Movsas B, Videtic GM, Willers H. ACR Appropriateness Criteria Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent. J Am Coll Radiol 10(9):654-664, 2013.
25. Welsh J, Amini A, Ciura K, Nguyen N, Palmer M, Soh H, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radio therapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim 38(4):442-447, 2013. PMID: 24200220.
26. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY. Adaptive/Nonadaptive Proton Radiation Planning and Outcomes in a Phase II Trial for Locally Advanced Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 84(5):1093-1100, 12/2012. e-Pub 4/2012. PMCID: PMC3409930.
27. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of five treatment strategies for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(5):1060-1070, 12/2012. e-Pub 9/2012. PMCID: PMC3776428.
28. Zhang X, Fang B, Mohan R, Chang JY. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother Oncol 105(2):250-257, 11/2012. e-Pub 9/2012. PMID: 23022172.
29. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting Radiation Pneumonitis After Stereotactic Ablative Radiation Therapy in Patients Previously Treated With Conventional Thoracic Radiation Therapy. Int J Radiat Oncol Biol Phys 84(4):1017-1023, 11/2012. e-Pub 4/2012. PMCID: PMC3612879.
30. Quan EM, Chang JY, Liao Z, Xia T, Yuan Z, Liu H, Li X, Wages CA, Mohan R, Zhang X. Automated Volumetric Modulated Arc Therapy Treatment Planning for Stage III Lung Cancer: How Does It Compare With Intensity-Modulated Radio Therapy? Int J Radiat Oncol Biol Phys 84(1):e69-76, 9/2012. PMCID: PMC3428745.
31. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg 94(3):914-920, 9/2012. e-Pub 7/2012. PMCID: PMC3468148.
32. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. Positron Emission Tomography for Assessing Local Failure after Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 85(5):1558-1565, 8/2012. e-Pub 5/2012. PMCID: PMC3474601.
33. Xiang ZL, Zeng ZC, Fan J, Tang ZY, He J, Zeng HY, Chang JY. The expression of HIF-1a in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep 39(2):2021-2029, 2/2012. e-Pub 6/2011. PMID: 21647551.
34. Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron Emission Tomography/Computed Tomography-Guided Intensity-Modulated Radiotherapy for Limited-Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 82(1):e91-97, 1/2012. e-Pub 4/2011. PMCID: PMC3465842.
35. Grosshans DR, Boehling, NS, Palmer M, Spicer C, Erice R, Cox JD, Komaki R and Chang JY. Alternative Beam Arrangements for IMRT Planning in Patients with Carcinoma of the Distal Esophagus. Practical Radiation Oncology 2:41-45, 2012.
36. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7(1):152, 2012. e-Pub 9/2012. PMCID: PMC3444889.
37. Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol 7(1):144, 2012. e-Pub 8/2012. PMCID: PMC3444399.
38. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012:261096, 2012. e-Pub 8/2012. PMCID: PMC3432385.
39. Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for non-small cell lung cancer. Pulm Med 84(1):69-76, 2012. e-Pub 7/2012. PMCID: PMC3413954.
40. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang JY, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after Failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg 94(4):1126, 2012.
41. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Chang JY. A Prospective Evaluation of Staging and Target Volume Definition of Lymph Nodes by (18)FDG PET/CT in Patients with Squamous Cell Carcinoma of Thoracic Esophagus. Int J Radiat Oncol Biol Phys 81(5):e759-765, 12/2011. e-Pub 4/2011. PMID: 21470788.
42. Decker RH, Langer CJ, Rosenzweig KE, Chang JY, Gewanter RM, Ginsburg ME, Kong FM, Lally BE, Videtic GM, Movsas B. ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancer. Am J Clin Oncol 34(5):537-544, 10/2011. PMID: 21946673.
43. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(1):91-96, 9/2011. e-Pub 6/2010. PMID: 20542388.
44. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, Swisher SG, Gillin M, Mohan R, Cox JD. Toxicity and Patterns of Failure of Adaptive/Ablative Proton Therapy for Early-Stage, Medically Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 80(5):1350-1357, 8/2011. e-Pub 1/2011. PMCID: PMC3117089.
45. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 117(13):3004-3013, 7/2011. e-Pub 1/2011. PMID: 21264827.
46. Peng Y, Vedam S, Chang JY, Gao S, Sadagopan R, Bues M, Balter P. Implementation of Feedback-Guided Voluntary Breath-Hold Gating for Cone Beam CT-Based Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys 80(3):909-917, 7/2011. e-Pub 4/2011. PMID: 21470784.
47. Register SP, Zhang X, Mohan R, Chang JY. Proton Stereotactic Body Radiation Therapy for Clinically Challenging Cases of Centrally and Superiorly Located Stage I Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 80(4):1015-1022, 7/2011. e-Pub 7/2010. PMCID: PMC2952351.
48. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-Wide Association Study of Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy. J Natl Cancer Inst 103(10):817-825, 5/2011. e-Pub 4/2011. PMCID: PMC3096796.
49. Nguyen GH, Murph MM, Chang JY. Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. Cancers (Basel) 3(1):1232-1252, 3/2011. PMCID: PMC3095975.
50. Ikushima H, Balter P, Komaki R, Hunjun S, Bucci MK, Liao Z, McAleer MF, Yu ZH, Zhang Y, Chang JY, Dong L. Daily Alignment Results of In-Room Computed Tomography-Guided Stereotactic Body Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys 79(2):473-480, 2/2011. e-Pub 4/2010. PMID: 20399032.
51. Gomez DR, Chang JY. Adaptive Radiation for Lung Cancer. J Oncol 2011, 2011. e-Pub 8/2010. PMCID: PMC2931378.
52. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 117(20):4707-4713, 2011. PMCID: PMC3174272.
53. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology 1:52, 2011. e-Pub 12/2011. PMCID: PMC3355954.
54. Shirvani SM and Chang JY. Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. Cancers 3:3432-3448, 2011.
55. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 78(5):1387-1393, 12/2010. e-Pub 4/2010. PMID: 20381271.
56. Gopal RS, Dubey S, Rosenzweig KE, Chang JY, Decker R, Gewanter RM, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. Int J Radiat Oncol Biol Phys 78(4):969-974, 11/2010. e-Pub 8/2010. PMID: 20813465.
57. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 Esophageal Cancer After Neoadjuvant Therapy and Surgery: An Orphan Status. Ann Thorac Surg 90(3):884-890, 9/2010. e-Pub 2010. PMID: 20732513.
58. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY. Intensity-modulated proton therapy reduces normal tissue doses compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB-non-small cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 77(2):357-366, 6/2010. e-Pub 8/2009. PMCID: PMC2868090.
59. Gewanter RM, Rosenzweig KE, Chang JY, Decker R, Dubey S, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. Curr Probl Cancer 34(3):228-249, May-Jun, 5/2010. PMID: 20541060.
60. Nelson C, Balter P, Morice RC, Bucci K, Dong L, Tucker S, Vedam S, Chang JY, Starkschall G. Evaluation of Tumor Position and PTV Margins Using Image Guidance and Respiratory Gating. Int J Radiat Oncol Biol Phys 76(5):1578-1585, 4/2010. e-Pub 2/2010. PMID: 20137865.
61. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8):pii: e12402, 2010. e-Pub 8/2010. PMCID: PMC2928273.
62. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Jiang GL, Chang JY. GTV spatial conformity between different delineation methods by (18)FDG PET/CT and pathology in esophageal cancer. Radiother Oncol 93(3):441-446, 12/2009. e-Pub 8/2009. PMID: 19682760.
63. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer 115(14):3233-3242, 7/2009. PMID: 19472405.
64. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with Esophageal Cancer Radiation Therapy. J Thorac Oncol 4(7):880-888, 7/2009. e-Pub 5/2009. PMID: 19458557.
65. Gayed IW, Liu HH, Wei X, Liao Z, Yusuf SW, Chang JY, Bassett R, Komaki R. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 4(2):179-184, 2/2009. PMCID: PMC19179893.
66. Ezhil M, Vedam S, Balter P, Choi B, Mirkovic D, Starkschall G, Chang JY. Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiat Oncol 4:4, 1/2009. PMCID: PMC2645420.
67. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 4(1):5, 1/2009. PMCID: PMC2651897.
68. Riegel AC, Chang JY, Vedam SS, Johnson V, Chi PC, Pan T. Cine Computed Tomography Without Respiratory Surrogate in Planning Stereotactic Radiotherapy for Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 73(2):433-441, 2009. e-Pub 7/2008. PMID: 18644683.
69. Vassiliev ON, Kry SF, Chang JY, Balter PA, Titt U, Mohan R. Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys 10(1):2880, 2009. e-Pub 1/2009. PMID: 19223837.
70. Wu X, Lu C, Ye Y, Chang JY, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18(11):955-965, 11/2008. PMCID: PMC2665725.
71. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967-971, 11/2008. PMCID: PMC18954709.
72. Gayed IW, Chang JY, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol 3(8):858-864, 8/2008. PMID: 18670303.
73. Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep 19(5):1071-1077, 5/2008. PMCID: PMC18425360.
74. Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14(9):2813-2823, 5/2008. PMCID: PMC18452149.
75. Kennedy MP, Jimenez CA, Chang JY, Fossella F, Eapen GA, Morice RC. Optimisation of bronchial brachytherapy catheter placement with a modified airway stent. Eur Respir J 31(4):902-903, 4/2008. PMCID: PMC18378785.
76. Qiao XY, Wang W, Zhou ZG, Gao XS, Chang JY. Comparison of efficacy of regional and extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 70(2):396-402, 2/2008. e-Pub 9/2007. PMID: 17855004.
77. Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol 3(2):177-186, 2/2008. PMCID: PMC18303441.
78. Nelson C, Balter P, Morice RC, Choi B, Kudchadker RJ, Bucci K, Chang JY, Dong L, Tucker S, Vedam S, Briere T, Starkschall G. A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. J Appl Clin Med Phys 9(4):2766, 2008. PMCID: PMC19020478.
79. Britton KR, Starkschall G, Liu H, Chang JY, Bilton S, Ezhil M, John-Baptiste S, Kantor M, Cox JD, Komaki R, Mohan R.. Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 73(1):94-102, 2008. e-Pub 10/2008. PMCID: PMC18929448.
80. Hui Z, Zhang X, Starkschall G, Li Y, Mohan R, Komaki R, Cox JD, Chang JY. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys 72(5):1385-1395, 2008. e-Pub 5/2008. PMCID: PMC18486357.
81. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69(5):1409-1416, 12/2007. e-Pub 9/2007. PMID: 17904303.
82. Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69(2):350-357, 10/2007. e-Pub 4/2007. PMID: 17467922.
83. Zhu G, Cao X, Chang JY, Milas L, Wallace S, Li C. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep 18(3)(3):645-651, 9/2007. PMID: 17671714.
84. Shioyama Y, Jang SY, Liu HH, Guerrero T, Wang X, Gayed IW, Erwin WD, Liao Z, Chang JY, Jeter M, Yaremko BP, Borghero YO, Cox JD, Komaki R, Mohan R. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 68(5):1349-1358(5):1349-1358, 8/2007. e-Pub 4/2007. PMID: 17446001.
85. Britton KR, Starkschall G, Tucker SL, Pan T, Nelson C, Chang JY, Cox JD, Mohan R, Komaki R. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 68(4):1036-1046, 7/2007. e-Pub 3/2007. PMID: 17379442.
86. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-785, 7/2007. e-Pub 4/2007. PMID: 17418967.
87. Liu HH, Balter P, Tutt T, Choi B, Zhang J, Wang C, Chi M, Luo D, Pan T, Hunjan S, Starkschall G, Rosen I, Prado K, Liao Z, Chang JY, Komaki R, Cox JD, Mohan R, Dong L. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 68(2):531-540, 6/2007. e-Pub 3/2007. PMID: 17398035.
88. Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, Komaki R, Cox JD, Balter PA, Liu H, Zhu XR, Mohan R, Dong L. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 67:906-914, 2007. PMCID: PMC17293240.
89. Nelson C, Starkschall G, Balter P, Morice RC, Stevens CW, Chang JY. Assessment of lung tumor motion and setup uncertainties using implanted fiducials. Int J Radiat Oncol Biol Phys 67:915-923, 2007. PMCID: PMC17293241.
90. Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67:389-396, 2007. PMCID: PMC17236963.
91. Takahashi N, Yang DJ, Kohanim S, Oh CS, Yu DF, Azhdarinia A, Kurihara H, Zhang X, Chang JY, Kim EE. Targeted functional imaging of estrogen receptors with (99m)Tc-GAP-EDL. Eur J Nucl Med Mol Imaging 34:354-362, 2007. PMCID: PMC17021817.
92. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65(4):1087-1096, 7/2006. e-Pub 5/2006. PMID: 16682145.
93. Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B. Surgical patterns of care in operable lung carcinoma treated with radiation. J Thorac Oncol 6(6):526-531, 7/2006. PMID: 17409912.
94. Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol 1(3):252-259, 3/2006. PMID: 17409865.
95. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Jr, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106:441-447, 2006. PMCID: PMC16342067.
96. Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24:4485-4491, 2006. PMCID: PMC16983118.
97. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Cgurueac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr., Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(6):548-582, 2006.
98. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 66:117-125, 2006. PMCID: PMC16765528.
99. Nelson C, Starkschall G, Chang JY. The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume. Int J Radiat Oncol Biol Phys 65:573-586, 2006. PMCID: PMC16690439.
100. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, Chang JY, Swafford J, Broemeling L, Liao Z. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 47:1756-1762, 2006. PMCID: PMC17079807.
101. Chang JY, Zhang X, Komaki R, Cheung R, Fang B. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 64:1482-1494, 2006. PMCID: PMC16580499.
102. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11:3342-3348, 2005. PMCID: PMC15867233.
103. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61:656-664, 2005. PMCID: PMC15708243.
104. Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77:247-253, 2005. PMCID: PMC16298001.
105. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res 11:2894-2898, 2005. PMCID: PMC15837739.
106. Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol 32:S92-98, 2005. PMCID: PMC16015542.
107. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res 11:6657-6668, 2005. PMCID: PMC16166445.
108. Wang H, Dong L, O'Daniel J, Mohan R, Garden AS, Ang KK, Kuban DA, Bonnen M, Chang JY, Cheung R. Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol 50:2887-2905, 2005. PMCID: PMC15930609.
109. Yang DJ, Bryant J, Chang JY, Mendez R, Oh CS, Yu DF, Ito M, Azhdarinia A, Kohanim S, Edmund Kim E, Lin E, Podoloff DA. Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex. Anticancer Drugs 15:255-263, 2004. PMCID: PMC15014359.
110. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1258-1267, 2004. PMCID: PMC15001271.
111. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Jr, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58:204-212, 2004. PMCID: PMC14697440.
112. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60:427-436, 2004. PMCID: PMC15380576.
113. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang JY, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following post-operative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9(6):476-484, Nov-Dec, 11/2003. PMID: 14740977.
114. Hung MC, Chang JY, Xing X. Preclinical and clinical study of HER-2/neu-targeting gene therapy. Adv Drug Deliv Rev 30:219-227, 1998.
115. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC. Safety study and characterization of E1A liposome complex gene delivery protocol in an ovarian cancer model. Gene Therapy:1538-1544, 1998. PMCID: PMC9930307.
116. Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14:561-568, 1997. PMCID: PMC9053854.
117. Chang JY, Xia W, Shao R, Hung MC. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene 13:1405-1412, 1996. PMCID: PMC8875978.
118. Chang JY, Yu D, Xia W, Hung MC. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 10:1947-1954, 1995.
119. Hung MC, Matin A, Chang JY, Xing XM, Sorgi F, Huang L, Yu D. HER-2/neu-targeting gene therapy. Gene 159:65-71, 1995. PMCID: PMC7607574.
120. Tang ZY, Liu KD, Fan Z, Lu JZ, Chang JY, Xi H, Schroder CH, Arosio P. A decade's studies on the immunotargeting therapy of hepatocellular carcinoma. Antibody, Immunoconjugates, and Radiopharm 6:155-165, 1993.
121. Georges RN, Mukhopadhyay T, Chang JY, Nancy Yen, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal installation of a retroviral antisense K-ras construct. Cancer Res 53:1743-1746, 1993. PMCID: PMC8467490.
122. Chang JY, Mukhodahyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4:451-460, 1993.
123. Chang JY, Tang ZY, Xie H, Yuan AN, Zhao HY, Lu JZ. Imaging and therapy of human hepatocellular carcinoma with radiolabeled monoclonal antibody. J Exp Clin Cancer Res 10:243-252, 1991.

Invited Articles

1. De Ruysscher D, Chang JY. Clinical controversies: proton therapy for thoracic tumors. Semin Radiat Oncol 23(2):115-119, 4/2013. PMID: 23473688.
2. Shirvani SM, Roth JA, Chang JY. Can stereotactic body radiation therapy (SBRT) in early stage tumors produce comparable success as surgery? Thoracic Surgery Clinic 23(3):369-381, 2013.
3. Selek U, Chang JY. Evolution of modern-era radiotherapy strategies for unresectable advanced non-small cell lung cancer. Lung Cancer Management 2(3):213, 2013.
4. Shirvani SM, Chang JY. Proton therapy for non–small cell lung cancer: current evidence and future directions. Thoracic Cancer 3:99-108, 2012.
5. Liu H, Chang JY. Proton therapy in clinical practice. Chin J Cancer 30(5):315-326, 5/2011. PMID: 21527064.
6. Lin SH, Chang JY. Esophageal cancer: diagnosis and management. Chin J Cancer 29(10):843-854, 10/2010. e-Pub 2010. PMID: 20868553.
7. Chang JY, Cox JD. Improving radiation conformality in the treatment of non-small cell lung cancer. Semin Radiat Oncol 20(3):171-177, 7/2010. PMCID: PMC2905742.
8. Chang JY, Roth JA. Stereotactic body radiation therapy for stage I NSCLC. Thoracic Surgery Clinics 17:251-259, 1/2007.
9. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep 7:255-259, 7/2005. PMID: 15946583.

Editorials

1. Chang JY, De Ruysscher D. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. J Thorac Dis 6(4):285-286, 4/2014. PMCID: PMC3968561.
2. Chang JY. Oncology scan-promising strategies for the treatment of locally-advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):1-4, 9/2013.
3. Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, and Yamashita H. Oligometastases/Oligo-Recurrence of Lung Cancer. Pulmonary medicine(438236), 2/2013.
4. Chang JY. Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges. J Thorac Dis 3(3):144-146, 9/2011. PMCID: PMC3256526.
5. Loo BW, Chang JY, Dawson L, Kavanagh BD, Koong A, Senan S, Timmerman R. Stereotactic ablative radiotherapy: What's in a name? Practical Radiation Oncology 1:38-39, 2011.
6. Chang JY. Telomerase: a potential molecular marker and therapeutic target for cancer. J Surg Oncol 87:1, 2004. PMID: 15112252.

Abstracts

1. Evans JD, Gomez DR, <b>Chang JY</b>, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac Isodose Distributions and Increases in Focal F-18-Fluorodeoxyglucose Uptake on Positron Emission Tomography After Thoracic Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 87(2S):S645, 10/2013.
2. Chang JY, Xu Q, Balter P, James W, Gomez D, Komaki R, Roth J, Swisher S. Clinical Outcome and Toxicity in Central Located Stage I or Isolated Recurrent Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 87(2S):S514-S515, 10/2013.
3. Grant JD, Sobremonte A, Hillebrandt E, Allen PK, Chang JY, Komaki R, Liao Z, Heymach JV, and Gomez D. Dosimetric Impact of Induction Chemotherapy on Subsequent Radiation Treatment Planning in Patients With Inoperable Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 87(2S):S536-S537, 10/2013.
4. Xiang Z, Hess K, Zhang X, Liang S, Chang JY. A Dosimetric Model for Predicting Radiation Pneumonitis After Stereotactic Ablative Radiotherapy for Stage I Non-small Cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 84(3S):S557, 11/2012.
5. Grant J, Gomez D. Zhuang Y, Chang JY, Komaki R, Fossella F, Gold K, Liao Z, and Cox J. Impact of Chemotherapy Response and Radiation Dose on Overall Survival in Patients With Inoperable Non-small Cell Lung Cancer Treated With Induction Chemotherapy Followed by Concurrent Chemoradiation. International Journal of Radiation Oncology, Biology, Physics 84(3S):S593, 11/2012.
6. Wang H, Gomez D, Komaki R, Welsh J, O’Reilly M, Chang JY, Zhuang Y, Levy L, Lu C, Liao Z. Improved Survival Outcomes in Non-small Cell Lung Cancer Patients with Incidental Concurrent Use of Beta-Blockers and Definitive Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 84(3S):S587, 11/2012.
7. Mohan R, Matney JE, Bluett J, Palmer M, Choi N, Chang JY, Komaki R, Cox J, Liao Z. IMRT Versus Passively Scattered Proton Therapy (PSPT) for Locally Advanced NSCLC - Impact of Changing Techniques and Technologies Over the Course of a Randomized Trial. International Journal of Radiation Oncology, Biology, Physics 84(3S):S565-566 (#2923), 11/2012.
8. Gomez DR, Liao K, Chang JY, Liao Z, Shirvani SM, Komaki R, Welsh JW, Heymach JV, Swisher SG, and Smith BD. Patient Selection for Treatment Modality in Stage III Non-small Cell Lung Cancer: A Population-based Analysis. International Journal of Radiation Oncology, Biology, Physics 84(3S):S540-541, 11/2012.
9. Shirvani SM, Juloori A, Gomez D, Allen PK, Komaki R, O'Reilly M, Liao Z, Welsh J, Papadimitrakopoulou V, Chang JY. Patterns of Failure for Limited-Stage Small Cell Lung Cancer Following Definitive Radiation Therapy in the Modern Era. International Journal of Radiation Oncology, Biology, Physics 84(3S):S595-596, 11/2012.
10. Zhuang Y, Gomez D, Komaki R, O'Reilly M, Welsh J, Lin SH, Chang JY, Jeter M, and Liao ZX. Prognostic Factors for Overall Survival in Stage IIIA/IIIB Non-small Cell Lung Cancer After Definitive (Chemo)radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 84(84):S591-592, 11/2012.
11. McAvoy S, Komaki R, Allen P, Rineer J, Liao X, Chang JY, Welsh J, Palmer M, Cox JD, Gomez D. Reirradiation with Proton Beam Therapy or Intensity Modulated Radiation Therapy for Non-Small Cell Lung Cancer: An Institutional Experience. International Journal of Radiation Oncology, Biology, Physics 84(3S):S608-609, 11/2012.
12. Liu Y, Balter P, Komaki R, Xu Q, Swisher S, Chang JY. Stereotactic Ablative Radiotherapy for Mutiple Primary Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 84(3S):S172-173 (#1016), 11/2012.
13. Gomez DR, Liao K, Chang JY, Liao Z, Shirvani SM, Komaki R, Welsh JW, Heymach JV, Swisher SG, and Smith BD. Treatment Modality and Other Prognostic Factors for Overall Survival in Stage III Non-Small Cell Lung Cancer (NSCLC): A Population-based Analysis. International Journal of Radiation Oncology, Biology, Physics 84(3S):S540, 11/2012.
14. Chang JY. Combined Modality Management and Imaging Guided Radiotherapy for Non-small Cell Lung Cancer. The Journal of JASTRO 16:29, 2007.

Book Chapters

1. Shirvani SM and Chang JY. Charged particles in stereotactic radiosurgery. In: Principles and Practice of Stereotactic Radiosurgery, 2nd. Ed(s) Lawrence S. Chin and William F. Regine. Springer. In Press.
2. Chang JY. Cancer of the lung. In: Technical basis of radiation therapy: Practical clinical applications, Fifth edition. Ed(s) Levitt SH, Purdy JA, Perez CA, Poortmans P. Springer, 755-775, 2012.
3. Truong MT, Gomez D, Chang JY and Mehran RJ. Pleural tumors. In: Oncologic Imaging: a muitidisciplinary approach. Ed(s) Sliverman PM. Elsevier, 79-93, 2012.
4. Chang JY, Shirvani SM, Loo BW, Lamond JP, Slotman B, Nagata Y. Primary lung cancer. In: Stereotactic Body Radiation Therapy. Springer: New York, 137-162, 2012. ISBN: 978-3-642-25604-2.
5. Christodouleas JP and Chang JY. Early stage non-small cell lung cancer. In: Radiation Oncology: a question-based review. Ed(s) Hristov B, Lin SH and Christodouleas JP. Lippincott Williams and Wilkins: Phyladelphia, 199-209, 2011.
6. Shirvani SM and Chang JY. Hypofractionated proton therapy in the treatment of non-small cell lung cancer. In: Hypofractionation: scientific concepts and clinical experiences. Ed(s) Pollack A and Ahmed MM. Lumi Text Publishing, 339-353, 2011.
7. Lin SH and Chang JY. Lung cancer. In: Decision making in Radiation Oncology. Ed(s) Liu JJ and Bradly LW. Springer: New York, 261-328, 2011.
8. Chang JY. Thorax. In: Uncertainties in external beam radiation therapy. Ed(s) Palta JR and Mackie TR. Medical Physics Publishing, 575-592, 2011.
9. Chang JY and Komaki R. Proton therapy in lung and thoracic cancers. In: Radiation Medicine Rounds: Proton Therapy. Ed(s) Metz J and Thomas C, Jr. Demos Medical Publishing: New York, 523-537, 2010.
10. Chang JY, Komaki R, Roth JA, Herbst r, Cox JD. Image guidance of combined modality management of NSCLC. In: Image-guided radiation therapy for lung cancer. Informa, 1-18, 2008.
11. Chang JY, Mohan R, Cox JD. Image-guided proton radiotherapy. In: Image-guided radiation therapy for lung cancer. Informa, 127-139, 2008.
12. Chang JY. Image-guided radiotherapy guidelines and techniques for NSCLC. In: Image-guided radiation therapy for lung cancer. Informa, 19-38, 2008.
13. Chang JY, Bradley J, Govindan R, Komaki R. Lung. In: Principles and Practice of Radiation Oncology, 5th. Ed(s) Halperin EC, Perez CA and Brady LW. 5th Edition. Lippincott Williams &Wilkin, 1076-1108, 2008.
14. Chang JY, Smith A, Cox JD. Proton therapy. In: Lung Cancer, 3. Ed(s) Roth JA, Cox JD, Hong WK. Blackwell Publishing Ltd, 271-282, 2008.
15. Chang JY, Balter P, Komaki R. Stereotactic body radiation therapy (SBRT) in stage I, selective stage II and isolated peripheral recurrent NSCLC. In: Image-guided radiation therapy for lung cancer. Informa, 93-102, 2008.
16. Onn A, Vaprociyan A, Chang JY, Komaki R, Roth JA, Herbst RS. Cancer of the lung. In: Cancer Medicine, 27. Ed(s) Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holand JF and Frei E. BC Decker Inc, 1179-1225, 2006.
17. Janjan NA, Strom E, Perkins G, Ha, C, Chang JY. Effects of radiation on the heart. In: Cancer and the Heart. BC Decker Inc, 75-113, 2006.
18. Komaki R, Chang JY, Liao Z, Cox JD, Mason KA, Milas L. Radioprotectors and chemoprotectors in the management of lung cancer. In: Medical Radiology-Radiation Oncology: Advances in radiation Oncology in lung cancer. 2.2.6. Springer-Verlag, 123-134, 2004.
19. Chang JY, Mukhopadhyay T, Georges RN, Roth JA. Molecular targeting of cancer: retroviral vector-mediated antisense nucleic acid therapy. In: Gene Therapy From Laboratory to the Clinic. 5. World Scientific Publishing Co: New Jersey, 70-106, 1994.
20. Chang JY. Immunotherapy of human hepatocellular carcinoma with lymphokine-activated killer cells and interleukin-2. In: The Advance in Primary Liver Cancer Research, 26. Shanghai Medical University Press, 263-272, 1990.

Books (edited and written)

1. Roth JA, Hong WK, Komaki R, Tsao A, Chang JY. Ed(s) Roth JA, Hong WK, Komaki R, Tsao A, Chang JY. Lung Cancer. Blackwell, 2014.
2. Cox JD, Chang JY, Komaki R. Image-guided radiation therapy for lung cancer. Taylor and Francis Group, 2008.

Grant & Contract Support

Title: 4D Robust Optimization in Intensity-Modulated Proton Therapy
Funding Source: NIH/NCI
Role: Co-Mentor
Principal Investigator: Wei Liu
Duration: 8/13/2012 - 7/31/2016
 
Title: Using the mdaccAutoPlan system to improve radiotherapy plan quality while reducing cost
Funding Source: MDACC
Role: Co-Principal Investigator
Principal Investigator: Xiaodong Zhang
Duration: 2012 - 2014
 
Title: Large-scale parallelized 4D worst-case robust optimization for intensity-modulated proton therapy
Funding Source: IRG
Role: Co-Investigator
Principal Investigator: Wei Liu
Duration: 9/1/2011 - 8/31/2013
 
Title: Advanced Volumetric Imaging and Adaptive Radiotherapy for Detecting and Correcting for Inter-fractional Changes
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: Peter Balter
Duration: 7/1/2011 - 6/30/2016
 
Title: Optimizing Proton Therapy - Project 4: Achieving “What You See is What You Get” in Proton Therapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: DeLaney Thomas
Duration: 9/2009 - 7/2014
 
Title: International randomized study to compare CyberKnife stereotactic radiosurgery with surgical resection in stage I NSCLC
Funding Source: Accuray
Role: Co-Principal Investigator
Principal Investigator: Jack A. Roth
Duration: 10/21/2008 - 5/31/2013
 
Title: Optimizing Proton Therapy - Project 1: Proton Dose Escalation and Proton vs. Photon Randomized Trials for Non-Small Cell Lung Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Thomas DeLaney
Duration: 9/25/2008 - 7/31/2014
 
Title: Lung cancer SPORE, project 2: Risk prediction for platinum-based chemotherapy and radiotherapy outcome in non-small cell lung cancer patients
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Xifeng Wu
Duration: 2008 - 2013
 
Title: Radiation sensitization by apoptotic gene therapy and molecular imaging of apoptosis in human lung cancer model
Funding Source: Radiological Society of North America (RSNA)
Role: Principal Investigator
Duration: 7/1/2004 - 7/1/2006

Last updated: 9/1/2014